NEW YORK--(BUSINESS WIRE)--SIGA Technologies, Inc. (NASDAQ: SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, announced today that it has successfully completed a multiple ascending dose human clinical trial with its lead smallpox drug candidate, ST-246. Volunteers received oral doses of 250 mg, 400 mg or 800 mg of ST-246 once a day for 21 days.
